NP Life Sciences Health Industry Group Inc. Files 2023 Annual Report

TL;DR

<b>NP Life Sciences Health Industry Group Inc. has filed its 2023 10-K report, detailing operations and financial standing.</b>

AI Summary

NP Life Sciences Health Industry Group Inc. (ACAT) filed a Annual Report (10-K) with the SEC on April 16, 2024. NP Life Sciences Health Industry Group Inc. filed its 10-K report for the fiscal year ending December 31, 2023. The company was formerly known as GJ Culture Group US, Inc. and changed its name on July 5, 2019. The company is incorporated in Nevada and operates in the Educational Services sector (SIC 8200). Key segments include Traditional Culture and Education, and Career Planning, Experience Sharing, and Guidance. The filing references related party members including NPLifeSciencesHealthSingaporePteLtdMember and GWHealthConsultingManagementIncMember.

Why It Matters

For investors and stakeholders tracking NP Life Sciences Health Industry Group Inc., this filing contains several important signals. The 10-K filing provides a comprehensive overview of the company's financial performance, business operations, and risk factors for the fiscal year 2023, which is crucial for investors to assess the company's health and future prospects. Information on related party transactions and customer concentration risks, as detailed in the filing, is important for understanding potential conflicts of interest and revenue stability.

Risk Assessment

Risk Level: medium — NP Life Sciences Health Industry Group Inc. shows moderate risk based on this filing. The company's business is subject to risks related to customer concentration, with specific mention of 'FourCustomersMember' and 'CustomerAMember' contributing to sales revenue, indicating potential vulnerability if these customers reduce their business.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand the company's operational performance and potential challenges.

Key Numbers

• 2023-12-31 — Fiscal Year End (Report period)
• 2024-04-16 — Filing Date (Date of submission)
• 8200 — SIC Code (Services-Educational Services)
• 2019-07-05 — Name Change Date (Former name GJ Culture Group US, Inc.)

Key Players & Entities

• NP Life Sciences Health Industry Group Inc. (company) — Filer name
• GJ Culture Group US, Inc. (company) — Former company name
• 2023-12-31 (date) — Fiscal year end
• 2024-04-16 (date) — Filing date
• Nevada (location) — State of incorporation
• NPLS:NPLifeSciencesHealthSingaporePteLtdMember (company) — Related party member
• NPLS:GWHealthConsultingManagementIncMember (company) — Related party member
• FourCustomersMember (company) — Customer concentration risk

FAQ

Risk Factors

• Customer Concentration Risk [medium — market]: The company's revenue is significantly dependent on a limited number of customers, including 'FourCustomersMember' and 'CustomerAMember', posing a risk if these relationships are negatively impacted.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K filing.
• 2024-04-16: Filing Date — Date the 10-K report was officially submitted to the SEC.

Glossary

10-K

An annual report required by the U.S. Securities and Exchange Commission (SEC), which gives a comprehensive summary of a company's financial performance. (This filing provides the official annual financial and business overview for NP Life Sciences Health Industry Group Inc.)

SIC Code

Standard Industrial Classification code used to classify businesses based on their primary activity. (Indicates NP Life Sciences Health Industry Group Inc. operates within the Educational Services sector.)

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value NPLS N/A Securities reg
• $99,599 — r ended December 31, 2022 and generated $99,599 in revenue in the fiscal year ended Dec
• $1,000 — on the such education is approximately $1,000 per person; and The number of people pa

Filing Documents

• form10-k.htm (10-K) — 759KB
• ex4-1.htm (EX-4.1) — 23KB
• ex31.htm (EX-31) — 12KB
• ex32.htm (EX-32) — 7KB
• form10-k_001.jpg (GRAPHIC) — 28KB
• form10-k_002.jpg (GRAPHIC) — 32KB
• form10-k_003.jpg (GRAPHIC) — 39KB
• form10-k_004.jpg (GRAPHIC) — 27KB
• form10-k_005.jpg (GRAPHIC) — 13KB
• report_001.jpg (GRAPHIC) — 8KB
• report_002.jpg (GRAPHIC) — 5KB
• 0001493152-24-014774.txt (&nbsp;) — 3432KB
• npls-20231231.xsd (EX-101.SCH) — 20KB
• npls-20231231_cal.xml (EX-101.CAL) — 29KB
• npls-20231231_def.xml (EX-101.DEF) — 71KB
• npls-20231231_lab.xml (EX-101.LAB) — 203KB
• npls-20231231_pre.xml (EX-101.PRE) — 162KB
• form10-k_htm.xml (XML) — 286KB

Legal Proceedings

Legal Proceedings 24 Item 4. Mine Safety Disclosures. 24 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. 24 Item 6.

Selected Financial Data

Selected Financial Data. 24 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations. 25 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk. 29 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data. 30 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure. 31 Item 9A.

Controls and Procedures

Controls and Procedures. 31 Item 9B. Other Information. 32 PART III Item 10. Directors, Executive Officers and Corporate Governance. 33 Item 11.

Executive Compensation

Executive Compensation. 36 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. 37 Item 13. Certain Relationships and Related Transactions, and Director Independence. 38 Item 14. Principal Accounting Fees and Services. 39 PART IV Item 15. Exhibits, Financial Statement Schedules. 39 2 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This annual report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve substantial risks and uncertainties. All statements, other than revenues, projected costs, prospects and plans and objectives of management are forward-looking statements. The words "anticipates," "believes," "continue," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would," the negative of these terms and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that the expectations underlying our forward-looking statements are reasonable, these expectations may prove to be incorrect, and all of these We have included important risks and uncertainties in the cautionary statements included in this annual report. We believe these risks and uncertainties could cause actual results or events to differ materially from the forward-looking statements that we make. Should one or more of these risks and uncertainties materialize, or should underlyin

View Full Filing

View this 10-K filing on SEC EDGAR